Abstract:Background: Group B streptococcus (GBS) surface protein epitopes are potential targets for development of vaccines that could confer protection against invasive GBS disease (IGbsD) irrespective of the capsular serotype. The aim of this study was to determine the association of natural acquired mother-newborn GBS surface proteins specific serum IgG and IGbsD during early infancy (<90 days age). Methods Clinical GBS isolates from 81 women who delivered either infant with IGbsD (n=38) and healthy controls (n=43) were assessed for surface expression of proteins Sip, GBS0393 and GBS206 using flow cytometry. Serum IgG titres to Sip, GBS0393 and GBS206 surface proteins were measured in paired maternal-infant sera on multiplex Luminex platform to determine IgG titres associated with reduce risk of IGbsD caused by GBS strains expressing homotypic protein. Results Infant sera IgG GMT in IGbsD cases caused by strains expressing Sip and GBS2016 were lower (64 and 61 U/ml, respectively) compared to healthy controls born to women colonized by strains expressing the respective proteins (145 and 151 U/mL, respectively, p<0.01). Moreover, increasing infant antibody titres against Sip and GBS2016 were associated with ≥80% adjusted disease risk (ADR) reduction to GBS isolates expressing homotypic proteins. Among women colonized with GBS isolates expressing GBS2106, mothers of cases had lower GBS2016-specific IgG GMT (249 U/mL) compared to mothers of controls (163 U/mL, adj-p=0.023). Conclusion. Increasing infant IgG titres to GBS2106 and Sip was associated with reduced IGbsD risk and therefore warranting further investigations as potential GBS vaccines and/or protein conjugants.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to determine the association between maternally - neonatally - serially - obtained natural IgG against specific group B Streptococcus (GBS) surface proteins and early - infant invasive GBS disease (IGbsD). Specifically, the study aims to evaluate whether the IgG levels in maternal and neonatal sera against Sip, GBS0393 and GBS206 surface proteins are related to the reduction of the risk of IGbsD caused by GBS strains expressing the same - type proteins. ### Background Group B Streptococcus (GBS) is one of the main causes of neonatal invasive diseases, and its case - fatality rate is between 2% - 20%. According to the time of onset, IGbsD can be divided into early - onset type (EOD, < 7 days) and late - onset type (LOD, 7 - 90 days). Maternal vaccination against GBS can theoretically prevent IGbsD in their infants. Previous studies have shown that the antibody level in maternal serum against the same - type serotype is negatively correlated with the risk of IGbsD in infants. ### Research Objectives The main objective of the study is to evaluate whether the levels of maternally - neonatally - serially - obtained natural IgG against GBS surface proteins Sip, GBS0393 and GBS206 are related to the reduction of the risk of IGbsD, especially in those infants whose mothers carry GBS strains expressing the same - type proteins. ### Methods - **Study Population**: A retrospective analysis was performed on serum samples from 83 mothers who had full - term deliveries and their infants. These infants were divided into a case group with IGbsD and a healthy control group. - **Recombinant Proteins**: The Sip, GBS0393, GBS1356 and GBS206 proteins were expressed in Escherichia coli by gene cloning technology and purified. - **Antibody Quantification**: The IgG levels against these surface proteins in maternal and infant sera were measured by multi - well immunofluorescence assay (Luminex platform). - **Bacterial Surface Staining**: The expression of Sip, GBS0393 and GBS206 proteins on the surface of clinical GBS strains was detected by flow cytometry. - **Statistical Analysis**: Data were analyzed using R and STATA software. The differences in IgG levels between the case group and the control group were compared, and the association between antibody levels and disease - risk reduction was estimated. ### Results - **Infant Serum IgG Levels**: In cases of IGbsD caused by GBS strains expressing Sip and GBS206 proteins, the geometric mean titer (GMT) of IgG in infant sera was significantly lower than that in the healthy control group (64 U/mL and 61 U/mL vs 145 U/mL and 151 U/mL respectively, p < 0.01). - **Antibody Titer and Disease Risk**: Increased infant anti - Sip and GBS206 antibody titers were associated with ≥ 80% adjusted disease risk (ADR) reduction. - **Maternal Serum IgG Levels**: In GBS strains expressing GBS206 protein, the GBS206 - specific IgG GMT in mothers of the case group was significantly lower than that in mothers of the control group (249 U/mL vs 163 U/mL, adj - p = 0.023). ### Conclusions Increased infant serum IgG titers against GBS2106 and Sip proteins are associated with a reduced risk of IGbsD. Therefore, these proteins are worthy of further study as potential GBS vaccines or protein conjugates.

Association of natural induced antibodies against select Group B streptococcus surface proteins and invasive disease in early infancy

Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis

Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy

Maternal GBS vaccination for preventing group B streptococcus disease in newborns: A mini review of current evidence

[Rapid Group B Streptococcus Screening Methods in Late Pregnancy and the Maternal-Neonatal Outcomes].

Antibody kinetics between birth and three months of life in healthy infants with natural exposure to Group B streptococcus: A UK cohort study

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines

Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates

A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization

Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

Surface Structures of Group B Streptococcus Important in Human Immunity

Distributions of Candidate Vaccine Targets, Virulence Factors, and Resistance Features of Invasive Group B Streptococcus Using Whole-Genome Sequencing: A Multicenter, Population-Based Surveillance Study

Serological responses to target Streptococcus pyogenes vaccine antigens in patients with proven invasive beta-haemolytic streptococcal infections

Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study

Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides

GBS vaccines in the UK: a round table discussion

Group B Streptococcus and Intraamniotic Inflammation and Infection

Preclinical development of a novel Group B Streptococcus (GBS) vaccine candidate for maternal immunization based upon the alpha‐like protein family of GBS surface proteins (Alp)

Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses

Interaction of Group B Streptococcus with the Female Reproductive Tract